HemaCare acquires new research services arm
US blood products and services provider HemaCare has added a new
research segment to the company with the acquisition of private US
firm Teragenix for $4.8m (€3.7m).
research segment to the company with the acquisition of private US
firm Teragenix for $4.8m (€3.7m).
The addition of Teragenix, a provider of human biological samples, quality control products and clinical trial management services, allows HemacCare to expand its service offerings into these new areas and attract a range of new biopharmaceutical and other research-focused organisations as clients.
"Teragenix has established a world wide network of clinical partners that provide it with a unique ability to collect and document biological samples essential for biomedical research," said Judi Irving, HemaCare's president and CEO.
"The research segment is a logical extension of our core blood products business and our strategic intention is to continue growing research sales both organically and through acquisition."
